MARKET

VSTM

VSTM

Verastem
NASDAQ
3.270
-0.200
-5.76%
After Hours: 3.300 +0.03 +0.92% 19:47 06/18 EDT
OPEN
3.500
PREV CLOSE
3.470
HIGH
3.500
LOW
3.200
VOLUME
606.89K
TURNOVER
0
52 WEEK HIGH
14.22
52 WEEK LOW
3.200
MARKET CAP
82.81M
P/E (TTM)
-0.7437
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VSTM last week (0610-0614)?
Weekly Report · 2d ago
Verastem: Market Overreaction Creates A Dip Buying Opportunity
Verastem's stock has dipped by about 70% following updated clinical data in serous ovarian cancer and pancreatic ductal adenocarcinoma. Reasons for the dip include a lower than previously reported ORR in LGSOC, plans for rolling NDA submission for KRAS-mutant patients, and serious adverse events in the PDAC study. Despite the dip, there may be a trading opportunity as the FDA has agreed to a rolling submission. Verastem is a biotech developing small molecule inhibitors targeting the RAS signaling pathways. The major risk is that VSTM will soon need to raise cash.
Seeking Alpha · 06/10 14:51
Weekly Report: what happened at VSTM last week (0603-0607)?
Weekly Report · 06/10 11:36
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
The law firm of Kirby McInerney LLP is investigating potential claims against Verastem, Inc. The investigation concerns whether the company violated the federal securities laws and/or engaged in other unlawful business practices. On May 23, 2024, the price ofVerastem shares declined by $8.06 per share.
Barchart · 06/07 16:02
Buy Rating Affirmed for Verastem Amid Promising Pancreatic Cancer Study Results
TipRanks · 06/06 10:29
Weekly Report: what happened at VSTM last week (0527-0531)?
Weekly Report · 06/03 11:39
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed from the index. 213 companies will be added and 198 deleted from the annual 2024 Russell index reconstitution. Inovio Pharmaceuticals, Nektar, Ocugen among notable additions.
Seeking Alpha · 05/30 20:55
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
Healthcare Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions. 225 securities will be added and 144 will be deleted as part of the annual reconstitution. The Russell 3000 index will have a new look on June 28.
Seeking Alpha · 05/30 19:54
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.